Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

VE Commercial Vehicles' sales up 37%
VE Commercial Vehicles today reported 37 per cent increase in sales in September at 2,558 units as against 1,865 units in the same month last year.

Novartis starts testing its swine flu vaccine
Swiss drugmaker Novartis has begun injecting its swine flu vaccine into people in the company"s first human tests, a spokesman said today.

News of the day

Bhupesh Bhandari: Korea's nuclear bomb
Some time in the summer of 1997, LG had thrown a party in Delhi. The Korean chaebol had set up shop in the country and was in a mood to celebrate. It had earlier joined hands with C K Birla but the joint venture fell through even before it could start. Globally, it had gone through a brand makeover from Lucky Goldstar to LG. It was now ready to have a go at India. At the party, K R Kim, the head of LG in India, took a few guests aside and said he knew how to make a nuclear bomb. The nasal voice was little more than a whine. Before anybody could ask how, he called a bearer, mixed whiskey in beer and handed it over to the guests — enjoy the nuclear bomb!
International Business

Zydus Cadila gets DCGI nod to conduct H1N1 vaccine trials

Drug maker Zydus Cadila today said it has received approval from the Drug Controller General of India (DCGI) to conduct clinical trials for the swine flu (H1N1) vaccine. - Zydus Cadila gets DCGI nod to conduct trials for H1N1 vaccine - Zydus completes acquisition of Simayla Pharma - Simayla becomes 100% Zydus subsidiary - Essential drugs list to be expanded - HC stops Zydus drug sale on Sun petition - Zydus Cadila net up 39% to Rs 132 cr With this approval "Zydus Cadila becomes the first Indian pharma company to commence multicentric clinical trials of its vaccine", the Ahmedabad-based firm said in a statement to the Bombay Stock Exchange. In recent times, the pandemic H1N1 Influenza has claimed thousands of lives across the globe. "With the vaccine in the market soon, we should be able to prevent further loss of lives to this infectious disease," Zydus Cadila Chairman and Managing Director Pankaj R Patel said. With the speedy completion of trials and the fast track approvals, the indigenous H1N1 vaccine is expected to hit the markets by April this year, the company said. According to the company, the demand for H1N1 vaccine in India is estimated to touch 50-60 million doses in initial phase. Zydus Cadila"s egg-based inactivated vaccine has been developed by the group"s experts at its Vaccine Technology Centre in Ahmedabad. Currently, the H1N1 vaccine market is estimated to be $676 million. The market is expected to cross $7 billion by 2011.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009